Alexion Pharmaceuticals Inc $ 110.55 -3.17 (-2.79%)
Warning! GuruFocus has detected 1 Severe warning sign with ALXN. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for ALXN (Alexion Pharmaceuticals Inc) from 1996 to Sep 21 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Alexion Pharmaceuticals stock (ALXN) PE ratio as of Sep 21 2020 is 29.51. More Details
Alexion Pharmaceuticals PE Ratio (TTM) Historical Data
View and export this data going back to 1996. Start your Free Trial
Alexion Pharmaceuticals PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:INCY NAS:MRNA NAS:SGEN NAS:BMRN NAS:ALNY NAS:SRPT NAS:NBIX NAS:BNTX NAS:TECH NAS:ACAD OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 XKRX:068270 HKSE:02269 OCSE:GMAB HKSE:01177 SZSE:300122
Traded in other countries ALXN.Austria A1LX34.Brazil AXP.Germany ALXN.Mexico ALXN.Switzerland 0QZM.UK ALXN.USA
Address 121 Seaport Boulevard, Boston, MA, USA, 02210
Alexion Pharmaceuticals Inc specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target other ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.